Objective
Platelets play an essential role in hemostasis but are also critically involved in acute arterial thrombotic occlusions leading to myocardial infarction or ischemic stroke and associated tissue fibrosis which are still the major cause of morbidity and disability in the European Union thus causing enormous costs in the health care system.
In the last years there is increasing evidence that primary hemostasis and inflammatory atherothrombosis are crucially affected by leukocytes. Thereby the neutrophils represent the most abundant type of immune celly as almost 50% of all leukocytes belong to the neutrophil subset. The neutrophil extracellular trap (NET) formation is mainly know as pro-thrombotic factor in arterial thrombosis and is characterized by release of decondensed chromatin with incorporated histones and neutrophil elastases after neutrophil activation. Beside their pro-thrombotic effect, NETs were also recently described as inducer of tissue fibrosis in vivo thus contributing to cardiac tissue damage. Although tubulin and intermediate filament rearrangements in the cytoskeleton and nuclear envelope are a prerequisite for NET formation and chromatin release, nothing is know about the underlying molecular mechanisms and targets hitherto.
Tubulin dynamics and microtubules are known regulators of intermediate filaments in the nuclear envelope thus maintaining the nuclear integrity of cells. Thereby, the ubiquitous Casein kinase 2 (CK2) is an acknowledged upstream molecule of microtubule dynamics and stability in a wide variety of cells. For this reason, the role of the CK2 in microtubule and intermediate filament dynamics during NET formation and its impact on thrombo-occlusive tissue fibrosis in cardiovascular diseases will be investigated resulting in the identification of new molecular structures suitable for improved and personalized treatment of thrombo-occlusive events like myocardial infarction and ischemic stroke.
Fields of science (EuroSciVoc)
CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques. See: https://op.europa.eu/en/web/eu-vocabularies/euroscivoc.
CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques. See: https://op.europa.eu/en/web/eu-vocabularies/euroscivoc.
- medical and health sciences clinical medicine angiology vascular diseases
- medical and health sciences clinical medicine cardiology cardiovascular diseases
- medical and health sciences basic medicine neurology stroke
You need to log in or register to use this function
We are sorry... an unexpected error occurred during execution.
You need to be authenticated. Your session might have expired.
Thank you for your feedback. You will soon receive an email to confirm the submission. If you have selected to be notified about the reporting status, you will also be contacted when the reporting status will change.
Programme(s)
Multi-annual funding programmes that define the EU’s priorities for research and innovation.
Multi-annual funding programmes that define the EU’s priorities for research and innovation.
-
H2020-EU.1.3. - EXCELLENT SCIENCE - Marie Skłodowska-Curie Actions
MAIN PROGRAMME
See all projects funded under this programme -
H2020-EU.1.3.2. - Nurturing excellence by means of cross-border and cross-sector mobility
See all projects funded under this programme
Topic(s)
Calls for proposals are divided into topics. A topic defines a specific subject or area for which applicants can submit proposals. The description of a topic comprises its specific scope and the expected impact of the funded project.
Calls for proposals are divided into topics. A topic defines a specific subject or area for which applicants can submit proposals. The description of a topic comprises its specific scope and the expected impact of the funded project.
Funding Scheme
Funding scheme (or “Type of Action”) inside a programme with common features. It specifies: the scope of what is funded; the reimbursement rate; specific evaluation criteria to qualify for funding; and the use of simplified forms of costs like lump sums.
Funding scheme (or “Type of Action”) inside a programme with common features. It specifies: the scope of what is funded; the reimbursement rate; specific evaluation criteria to qualify for funding; and the use of simplified forms of costs like lump sums.
MSCA-IF-GF - Global Fellowships
See all projects funded under this funding scheme
Call for proposal
Procedure for inviting applicants to submit project proposals, with the aim of receiving EU funding.
Procedure for inviting applicants to submit project proposals, with the aim of receiving EU funding.
(opens in new window) H2020-MSCA-IF-2017
See all projects funded under this callCoordinator
Net EU financial contribution. The sum of money that the participant receives, deducted by the EU contribution to its linked third party. It considers the distribution of the EU financial contribution between direct beneficiaries of the project and other types of participants, like third-party participants.
72074 Tuebingen
Germany
The total costs incurred by this organisation to participate in the project, including direct and indirect costs. This amount is a subset of the overall project budget.